BiotechTube

erythropoietin beta

Phase 2Completed
0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Aneurysmal Subarachnoid Hemorrhage

Conditions

Aneurysmal Subarachnoid Hemorrhage

Trial Timeline

Apr 1, 2005 → Mar 1, 2007

NCT ID
NCT00140010

About erythropoietin beta

erythropoietin beta is a phase 2 stage product being developed by Roche for Aneurysmal Subarachnoid Hemorrhage. The current trial status is completed. This product is registered under clinical trial identifier NCT00140010. Target conditions include Aneurysmal Subarachnoid Hemorrhage.

What happened to similar drugs?

0 of 4 similar drugs in Aneurysmal Subarachnoid Hemorrhage were approved

Approved (0) Terminated (1) Active (3)
🔄Clazosentan + PlaceboIdorsiaPhase 3
❌Clazosentan 5 m/h + Clazosentan 15 mg/h + PlaceboIdorsiaPhase 3
🔄Clazosentan + PlaceboIdorsiaPhase 3
🔄GTX-104 + Nimotop 30 MG Oral CapsuleGrace TherapeuticsPhase 3

Hype Score Breakdown

Clinical
12
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00140010Phase 2Completed

Competing Products

8 competing products in Aneurysmal Subarachnoid Hemorrhage

See all competitors
ProductCompanyStageHype Score
DenosumabAmgenPhase 2
31
Clazosentan + PlaceboIdorsiaPhase 3
34
ClazosentanIdorsiaPhase 2
29
Clazosentan 5 m/h + Clazosentan 15 mg/h + PlaceboIdorsiaPhase 3
26
Clazosentan + PlaceboIdorsiaPhase 3
34
Clazosentan 1 mg/h + Clazosentan 5 mg/h + Clazosentan 15 mg/h + PlaceboIdorsiaPhase 2
29
GTX-104 + Nimodipine CapsulesGrace TherapeuticsPhase 1
19
GTX-104 + Nimotop 30 MG Oral CapsuleGrace TherapeuticsPhase 3
34